Insider Transactions in Q4 2022 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q4 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2022
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
722
-10.83%
|
$3,610
$5.44 P/Share
|
|
Nov 18
2022
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
1,785
-1.53%
|
$8,925
$5.44 P/Share
|
|
Nov 18
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
530
-0.84%
|
$2,650
$5.44 P/Share
|
|
Nov 18
2022
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
722
-1.04%
|
$3,610
$5.44 P/Share
|
|
Nov 18
2022
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
1,139
-3.22%
|
$5,695
$5.44 P/Share
|
|
Nov 17
2022
|
Paul K. Audhya CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,419
+26.62%
|
-
|
|
Nov 17
2022
|
Thomas Andrew Crockett CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,805
+4.74%
|
-
|
|
Nov 17
2022
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,774
+2.74%
|
-
|
|
Nov 17
2022
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,419
+3.38%
|
-
|
|
Nov 17
2022
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,774
+4.78%
|
-
|